Domingo J L, Gomez M, Sanchez D J, Llobet J M, Keen C L
School of Medicine, 'Rovira i Virgili' University, Reus, Spain.
Mol Cell Biochem. 1995;153(1-2):233-40. doi: 10.1007/BF01075942.
The possible use of vanadium compounds in the treatment of diabetic patients is now being evaluated. However, previously to establish the optimal maximum dose for diabetes therapy, it should be taken into account that vanadium is a highly toxic element to man and animals. The toxic effects of vanadium are here reviewed. The tissue vanadium accumulation, which would mean an additional risk of toxicity following prolonged vanadium administration is also discussed. Recently, it has been shown that coadministration of vanadate and TIRON, an effective chelator in the treatment of vanadium intoxication, reduced the tissue accumulation of this element, decreasing the possibility of toxic side effects derived from chronic vanadium administration without diminishing the hypoglycemic effect of vanadium. However, previously to assess the effectiveness of this treatment in diabetic patients, a critical reevaluation of the antidiabetic action of vanadium and its potential toxicity is clearly needed.
目前正在评估钒化合物在糖尿病患者治疗中的潜在用途。然而，在确定糖尿病治疗的最佳最大剂量之前，应考虑到钒对人和动物是一种剧毒元素。本文综述了钒的毒性作用。还讨论了组织钒蓄积问题，这意味着长期服用钒后会增加毒性风险。最近有研究表明，同时给予钒酸盐和TIRON（一种治疗钒中毒的有效螯合剂）可减少该元素在组织中的蓄积，降低长期服用钒产生毒副作用的可能性，同时又不减弱钒的降血糖作用。然而，在评估这种治疗方法对糖尿病患者的有效性之前，显然需要对钒的抗糖尿病作用及其潜在毒性进行严格的重新评估。
